Publication Name	World Journal of Hepatology
Manuscript ID	110247
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Randomized Controlled Trial
Article Title	Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites
Manuscript Source	Unsolicited Manuscript
All Author List	Yuan Gao, Yun-Yi Gao, Rong-Ya Shi, Dong Ji, Yu Wang, Liang Xu, Qi Wang, Meng-Hua Wu, Han-Lu You, Qiu-Shi Bu, Yi-Xi Dong, Long-Zhen Zhou, Wei Liu, Qing-Kun Song, Ying Han, Hou Wei, Xin-Yu Zhang and Zhong-Jie Hu
Funding Agency and Grant Number	Funding Agency Grant Number Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support ZLRK202533 High-Level Public Health Technology Talent Project 2022-2-005
Corresponding Author	Zhong-Jie Hu, Chief Physician, Professor, Senior Researcher, Senior Scientist, Vice General Manager, Department of Liver Disease Center, Beijing You’an Hospital, Capital Medical University, No. 8 Xitoutiao outside You’anmen, Fengtai District, Beijing 100069, China. yfcyt@139.com
Key Words	Sodium-glucose co-transporter 2 inhibitor; Empagliflozin; Cirrhosis; Ascites; Fractional excretion of sodium
Core Tip	Refractory ascites reflects proximal tubular sodium retention and frequent diuretic resistance in cirrhosis. We present a multicenter randomized protocol testing empagliflozin, a sodium-glucose co-transporter 2 inhibitor that promotes proximal tubular natriuresis without renin-angiotensin-aldosterone system stimulation, for refractory cirrhotic ascites. The trial compares empagliflozin plus standard care versus standard care over 14 days. Primary endpoint is change in fractional excretion of sodium; secondary outcomes include 24-hour urinary sodium, urine volume, ascites by ultrasound, body weight, and prespecified clinical safety parameters.
Citation	<p>Gao Y, Gao YY, Shi RY, Ji D, Wang Y, Xu L, Wang Q, Wu MH, You HL, Bu QS, Dong YX, Zhou LZ, Liu W, Song QK, Han Y, Wei H, Zhang XY, Hu ZJ. Effect of empagliflozin on fractional excretion of sodium in patients with cirrhosis and refractory ascites. <i>World J Hepatol</i> 2025; 17(10): 110247</p>

Received	2025-06-04 03:26
Peer-Review Started	2025-06-04 03:26
To Make the First Decision
Return for Revision	2025-06-26 08:06
Revised	2025-07-09 06:01
Second Decision	2025-09-19 02:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-09-19 10:02
Articles in Press	2025-09-19 10:02
Publication Fee Transferred	2025-07-14 04:46
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-10-17 06:15

ISSN	1948-5182 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com